Subscribe
Share
Share
Embed
Histology comes first, because adenocarcinoma and squamous cell carcinoma differ in cause, location, and treatment before surgery. Two patients with T3 N1 M0 disease carry the episode. The first, a man with distal adenocarcinoma, is taken through risk factors, then staging in a fixed order: endoscopy, CT, PET-CT, and endoscopic ultrasound last. Next come the TNM definitions and what each depth decides, then perioperative FLOT versus chemoradiation, esophagectomy at a high-volume center, and postoperative strictures and reflux. The second patient, with squamous cell carcinoma, shows chemoradiation before surgery, adjuvant nivolumab for residual disease, and definitive chemoradiation without surgery. Metastatic disease and common board traps close the episode.
Topics covered
Key decisions
This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: hello@boardpearls.com.
The most complete gastroenterology board-review podcast on the web, and it is entirely free. This is the GI series from Board Pearls: board review built around clinical reasoning, not recall. Every episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. No trivia, no textbook dictation, just the thinking that earns the point.
Over 100 episodes span the full blueprint across nine modules (esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics), grouped by chapter and built from the guidelines and pivotal trials the boards are written from: ACG, AGA, AASLD, and ASGE.
Pair it with the written curriculum, question bank, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode three of three of the Barrett Esophagus and Esophageal Cancer chapter, in the Esophageal Disorders module. This episode is esophageal cancer, through two patients. A seventy-one-year-old man with adenocarcinoma of the distal esophagus is followed from his first endoscopy through staging, treatment, and the problems after surgery. His case teaches why the histology is settled first, the order of staging and the reason for it, what each stage decides, which treatment before surgery fits adenocarcinoma, and what the gastroenterologist manages afterward. A sixty-year-old woman with squamous cell carcinoma at the same stage teaches how histology changes the treatment before surgery, when immunotherapy follows surgery, and when chemoradiation replaces surgery altogether.
Here's the first patient. A seventy-one-year-old man has four months of progressive dysphagia, first to meat, now to bread, with eighteen pounds of weight loss. He's had reflux for decades, he's obese, and he smoked for thirty years. Endoscopy shows an ulcerated mass in the distal esophagus extending to the gastroesophageal junction, with salmon-colored Barrett mucosa above it. Biopsies show adenocarcinoma.
His story is the warning pattern for esophageal cancer: solid-food dysphagia that's steadily progressing, in an older patient, with real weight loss. A narrowing that tightens over months with weight loss is cancer until proven otherwise, and that's why he went straight to endoscopy. He has esophageal adenocarcinoma. The histology is established first because the two types of esophageal cancer are almost different diseases, with different causes, different locations, and, for locally advanced disease, different treatments before surgery.
Adenocarcinoma is the most common type in the United States, and its incidence has risen three- to six-fold over the past three decades. It sits in the distal third of the esophagus, around the gastroesophageal junction. It's driven by reflux, central obesity, smoking, and Barrett esophagus. The risk factors that trigger Barrett screening are the same ones that predict adenocarcinoma: chronic reflux, central obesity, white race, male sex, age fifty or older, smoking, and a first-degree relative with Barrett esophagus or adenocarcinoma. Familial Barrett esophagus with autosomal dominant inheritance has been described, which is why family history is one of those criteria. Helicobacter pylori with gastritis of the gastric body that lowers acid output appears protective in some series, but eradicating it or leaving it in place isn't used to prevent esophageal cancer.
Squamous cell carcinoma is the most common type worldwide, about ninety percent of cases, and it has declined in the United States. It sits mainly in the upper and middle thoracic esophagus. Tobacco and alcohol cause it, and their risks multiply each other. Very hot beverages, above sixty-five degrees Celsius, are classified by the World Health Organization as a probable carcinogen. Achalasia causes food stasis and chronic injury to the lining, with a lifetime squamous cell risk of roughly seven tenths of a percent to just over three percent across series. A lye stricture gives rise to squamous cell carcinoma decades after the ingestion. Lichen planus and, in some populations, human papillomavirus also contribute. Tylosis, also called Howel-Evans syndrome, is an autosomal dominant thickening of the palms and soles caused by germline mutations in RHBDF2, with a lifetime squamous cell risk approaching ninety-five percent by age sixty-five.
Checked against both lists, his history points one way. Reflux, obesity, smoking, Barrett mucosa above the tumor, and a distal location all fit adenocarcinoma, and the biopsy confirms it.
With the histology known, staging decides what's possible for him, and it runs in a fixed order. Upper endoscopy with biopsies makes the diagnosis, gives the histology, and shows the gross extent, and for him that's done. Computed tomography, CT, of the chest and abdomen with contrast follows, because it shows local extent, enlarged regional nodes, and distant metastases. Positron emission tomography with CT, PET-CT, comes after that, because it finds distant metastases that CT misses and improves metastasis staging, which matters most in a patient being considered for cure; finding a metastasis changes the goal from cure to palliation. Endoscopic ultrasound comes last, because it gives the most accurate local staging: how deep the tumor goes and which regional nodes are involved, with fine-needle aspiration of suspicious nodes to give a tissue diagnosis that can change the stage.
The reason for that order is that if CT or PET shows distant metastases, the precise local depth no longer changes his treatment, and the invasive test would have been done for nothing. So staging looks far before it looks close. The one exception is a small, visible lesion that might be confined to the mucosa or just below it. For that lesion, endoscopic mucosal resection or endoscopic submucosal dissection is the staging test, because forceps biopsies can't measure depth of invasion, and the resected specimen gives the definitive T stage.
His results are read against the tumor, node, metastasis, or TNM, definitions. Tis is high-grade dysplasia; the columnar classification no longer uses the term carcinoma in situ. T1 invades the lamina propria, muscularis mucosae, or submucosa: T1a stays within the lamina propria or muscularis mucosae, and T1b crosses into the submucosa. T2 invades the muscularis propria. T3 invades the adventitia. T4a invades neighbors that can be resected, such as the pleura, pericardium, or diaphragm. T4b invades structures that can't, such as the aorta, a vertebral body, or the trachea. Nodes are counted: N0 is none, N1 is one to two regional nodes, N2 is three to six, and N3 is seven or more. M0 is no distant metastasis, and M1 is any distant metastasis, including nodes outside the regional basin.
His CT shows no distant disease. PET shows uptake only in the tumor and one nearby node. Endoscopic ultrasound shows the tumor through the muscularis propria into the adventitia, with one enlarged node that aspiration confirms is malignant. He's T3 N1 M0: locally advanced, but curable.
His treatment follows from that stage, because each depth carries a different risk of node spread. T1a, intramucosal cancer, is treated endoscopically in most patients, with mucosal resection or submucosal dissection and then radiofrequency ablation of the remaining Barrett mucosa. Node risk is under two percent for the two most superficial mucosal levels and stays low enough at the deepest mucosal level that endoscopic management is acceptable for most patients.
T1b, submucosal invasion, crosses the surgical threshold for most patients, because nodal risk rises sharply with depth into the submucosa, to as high as two thirds. The exception is the most superficial submucosal lesion with low-risk features: invasion under five hundred micrometers, well or moderately differentiated, and no lymphovascular invasion. American Gastroenterological Association guidance allows endoscopic management for that lesion, particularly in a poor surgical candidate. Deeper submucosal invasion belongs to esophagectomy.
T2 without nodes is also generally surgical, and both upfront esophagectomy and neoadjuvant chemoradiation followed by surgery are reasonable, because the benefit of treatment before surgery is debated at this stage. Locally advanced disease, T3 or T4a, or any node-positive disease without metastasis, gets multimodality treatment followed by esophagectomy, because treatment before surgery improves survival over surgery alone. Metastatic disease is palliative, with systemic therapy plus radiation, stenting, or other measures aimed at symptoms. He's T3 N1, so he gets treatment before surgery.
Which treatment comes before surgery is where his histology decides. Neoadjuvant chemoradiation was the first approach shown to improve survival over surgery alone in resectable locally advanced esophageal and junctional cancer, in a trial that included both histologies. The regimen is weekly carboplatin, dosed to an area under the curve of two, plus paclitaxel fifty milligrams per square meter for five weeks, with forty-one point four gray of radiation in twenty-three fractions. It roughly doubled median overall survival.
Perioperative chemotherapy then came to adenocarcinoma from the stomach. The regimen is fluorouracil, leucovorin, oxaliplatin, and docetaxel, FLOT: fluorouracil two thousand six hundred milligrams per square meter, leucovorin two hundred, oxaliplatin eighty-five, and docetaxel fifty, given as four cycles before surgery and four after. In resectable gastric and junctional adenocarcinoma, it improved survival over the older regimen of epirubicin, cisplatin, and fluorouracil or capecitabine, and it became the perioperative standard there. When FLOT and chemoradiation were then compared head to head in esophageal adenocarcinoma, FLOT improved overall survival. So for adenocarcinoma of the esophagus or junction, FLOT is preferred in a patient fit enough to tolerate it, and chemoradiation remains the option for an adenocarcinoma patient who can't. He's seventy-one but fit, so he receives perioperative FLOT.
Where he has surgery matters as much as which operation. Operative mortality for esophagectomy ranges from two to ten percent, depending on how many the center does, and complications occur in thirty to forty percent: anastomotic leak, anastomotic stricture, chylothorax, atrial fibrillation, and pneumonia, and later dumping, diarrhea, and reflux. Outcomes are better at high-volume centers, where the average stay is seven to ten days, so he's referred to one. The approaches are transthoracic, either Ivor Lewis or three-field McKeown, and transhiatal. Ivor Lewis is favored for a distal adenocarcinoma like his, and the three-field or transhiatal approach is chosen by tumor location and surgeon preference. He completes his four cycles before surgery, has an Ivor Lewis esophagectomy, and then completes the four cycles after.
After surgery, two problems are common, and both come back to the gastroenterologist. An anastomotic stricture develops in ten to thirty percent of patients after esophagectomy. He'd present with new dysphagia months after surgery, and it responds to balloon dilation in most cases. Reflux is common and chronic, because the operation destroys the antireflux barrier, so a proton pump inhibitor, PPI, for life is standard.
The second patient shows how the same stage is treated differently when the histology is squamous. A sixty-year-old woman has smoked and drunk heavily for forty years. She has a mid-thoracic squamous cell carcinoma, staged the same way, as T3 N1 M0.
Her location and history fit squamous cell carcinoma, and her treatment before surgery is different. For resectable squamous cell carcinoma, the standard is neoadjuvant chemoradiation: weekly carboplatin and paclitaxel for five weeks with forty-one point four gray in twenty-three fractions, followed by esophagectomy. Squamous tumors respond especially well. About half show no residual tumor at all in the resected specimen, roughly twice the rate in adenocarcinoma, and the absolute survival benefit of chemoradiation is larger in squamous cell carcinoma. That's why the regimen before surgery follows histology.
What's found at surgery decides her next step. If any tumor remains in the specimen after chemoradiation, meaning anything other than no tumor and no nodes, she gets adjuvant nivolumab, two hundred forty milligrams every two weeks for sixteen weeks, then four hundred eighty milligrams every four weeks, for up to a year. In that setting it doubled disease-free survival. If there's no residual disease, she doesn't need it.
If she weren't a surgical candidate, definitive chemoradiation would be the curative-intent treatment for her squamous cell carcinoma, without surgery. It's also preferred over surgery for cervical and very proximal squamous tumors, where the surgical anatomy is unfavorable. The dose is fifty point four gray in twenty-eight fractions with concurrent cisplatin and fluorouracil, or carboplatin and paclitaxel. Five-year survival with that approach in squamous cell carcinoma is about a quarter, similar to or slightly better than when it's used for adenocarcinoma.
Her risk factors also bear on surveillance for other patients at squamous risk. Achalasia raises squamous cell risk, but routine surveillance isn't recommended, because the American Society for Gastrointestinal Endoscopy finds insufficient evidence to support it. After lye ingestion with a chronic stricture, cancer can arise decades later, and surveillance is reasonable. Tylosis carries a risk approaching ninety-five percent by sixty-five, so those families are managed as a hereditary cancer syndrome.
Either patient could have presented with metastatic disease, and then treatment would be for symptoms and survival. For dysphagia, a self-expanding metal stent is the standard way to reopen the lumen, with photodynamic therapy or external-beam radiation as options when stenting fails. Systemic treatment for metastatic adenocarcinoma is a platinum and fluoropyrimidine doublet, with nivolumab or pembrolizumab added for tumors that express programmed death-ligand one, PD-L1, and trastuzumab added for tumors positive for human epidermal growth factor receptor two, HER2, so both markers are tested. Metastatic squamous cell carcinoma gets the same chemotherapy backbone plus pembrolizumab or nivolumab. Five-year survival in metastatic disease remains under five percent.
Here are the traps the boards set in these patients.
In staging, ordering endoscopic ultrasound before CT and PET wastes an invasive test when distant disease would make the local depth irrelevant. And relying on forceps biopsies or ultrasound to stage an early visible lesion misses its true depth, which only endoscopic resection defines.
In stage-based treatment, sending a T1a cancer to surgery overtreats a lesion with little node risk. Sending a deep T1b cancer to endoscopic treatment undertreats one with high node risk; only a superficial, low-risk submucosal lesion can stay endoscopic.
In treatment before surgery, defaulting to chemoradiation for a fit patient with adenocarcinoma passes over the regimen that improved survival, perioperative FLOT. Giving FLOT for squamous cell carcinoma passes over the standard, chemoradiation. Forgetting adjuvant nivolumab for residual disease after chemoradiation and surgery gives up a doubling of disease-free survival. And for a squamous patient who can't have surgery, or who has a cervical tumor, definitive chemoradiation is the curative option.
After surgery, sending a patient to a low-volume center for esophagectomy raises his operative risk. And forgetting the lifelong PPI, or failing to recognize new dysphagia months later as an anastomotic stricture to dilate, leaves treatable problems untreated.
So, start to finish.
Adenocarcinoma is distal and follows reflux, obesity, smoking, and Barrett esophagus. Squamous cell carcinoma is mid-thoracic and follows tobacco, alcohol, very hot drinks, achalasia, lye, and tylosis. Staging runs endoscopy, CT, PET-CT, then endoscopic ultrasound, and endoscopic resection stages any early visible lesion.
T1a is treated endoscopically; submucosal invasion is usually surgical, except a superficial low-risk lesion. Locally advanced disease gets treatment before esophagectomy at a high-volume center: perioperative FLOT for adenocarcinoma and chemoradiation for squamous cell carcinoma. Residual disease after chemoradiation and surgery earns a year of nivolumab. Definitive chemoradiation is for squamous patients who can't have surgery or who have cervical tumors.
After surgery, strictures are dilated and a PPI continues for life. Metastatic disease is palliated with stents and systemic therapy, with PD-L1 and HER2 testing guiding the added drugs.
The next chapter is the other inflammatory diseases of the esophagus: eosinophilic esophagitis from diagnosis through refractory disease, and the infections and chemical injuries that cause esophagitis.